Literature DB >> 28214482

Catheter-directed, ultrasound-assisted thrombolysis is a safe and effective treatment for pulmonary embolism, even in high-risk patients.

Kristen A Lee1, Andrew Cha2, Mark H Kumar2, Combiz Rezayat2, Clifford M Sales3.   

Abstract

OBJECTIVE: We sought to assess the early success and safety of catheter-directed, ultrasound-assisted (CDUA) thrombolysis for acute pulmonary embolism (PE) in patients deemed to be "high risk" for thrombolytic therapy.
METHODS: A retrospective evaluation of patients who underwent CDUA pulmonary thrombolysis in our practice during 39 months is reported. There were 91 patients considered, all of whom presented with acute PE as diagnosed by computed tomography angiography. The ratio of the right ventricle to left ventricle diameter (RVaxial:LVaxial) was noted, as were preprocedure pulmonary artery pressures (PAPs). Demographic data, significant medical history, and procedure details were recorded. Standard thrombolysis protocol was followed (1 mg of tissue plasminogen activator per hour per catheter after an initial 2-mg bolus per catheter). Minitab 17 (Minitab Inc, State College, PA) was used for data analysis.
RESULTS: There were 91 patients who had a computed tomography diagnosis of acute PE and pulmonary hypertension (PAP >25 mm Hg). Seventeen patients (19%) were deemed to be at high risk for bleeding, predicted by recent hemorrhage, major surgery within 3 weeks, acute myocardial infarction, and cardiac arrest with cardiopulmonary resuscitation within 1 week. The high-risk patients in our study were noted to have higher RV:LV ratios and lower oxygen saturations on admission (P < .05). On computed tomography angiography, the mean pretherapy RVaxial:LVaxial ratio was 1.5 ± 0.4. The mean pretherapy PAP was 56.2 ± 15.2 mm Hg. After 18.5 ± 3.5 hours of thrombolysis, the mean post-therapy PAP was 34.3 ± 10.4 mm Hg, with a pressure drop of 21.9 ± 4.8 mm Hg (39% decrease; P < .001). In total, seven patients (8%) suffered bleeding complications that required intervention-four gastrointestinal bleeds, a rectus sheath hematoma, and one gross hematuria. Three of the seven complications occurred in the high-risk group (3/17) and the other four in the general population of patients (4/74; P = .118). Minor bleeding complications (n = 14 [15%]) did not require intervention and included puncture site hematomas, ecchymosis, and mild traumatic hematuria. Considering all bleeding complications, increasing RVaxial:LVaxial ratio was a predictor of any bleeding complication, independent of all risk factors (P = .005).
CONCLUSIONS: CDUA thrombolysis for acute PE effectively reduced mean PAPs. Given the low incidence of major bleeding complications, even in those deemed to be clinically at high risk for bleeding, we additionally conclude that this procedure can be performed safely. Although larger studies with longer follow-up are necessary, CDUA pulmonary thrombolysis for the management of acute submassive PE appears to be effective in decreasing right-sided heart strain and can be performed with an acceptable risk profile.
Copyright © 2016 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28214482     DOI: 10.1016/j.jvsv.2016.10.075

Source DB:  PubMed          Journal:  J Vasc Surg Venous Lymphat Disord


  9 in total

Review 1.  Catheter-Directed Thrombolysis for Submassive Pulmonary Embolism.

Authors:  Matthew A Chiarello; Akhilesh K Sista
Journal:  Semin Intervent Radiol       Date:  2018-06-04       Impact factor: 1.513

2.  Catheter directed compared to systemically delivered thrombolysis for pulmonary embolism: a systematic review and meta-analysis.

Authors:  Ahmed K Pasha; Muhammad Umer Siddiqui; Muhammad Danial Siddiqui; Adnan Ahmed; Ammar Abdullah; Irbaz Riaz; M Hassan Murad; Haraldur Bjarnason; Waldemar E Wysokinski; Robert D McBane
Journal:  J Thromb Thrombolysis       Date:  2021-08-31       Impact factor: 2.300

Review 3.  Rationale for catheter directed therapy in pulmonary embolism.

Authors:  Sailen G Naidu; Martha-Gracia Knuttinen; J Scott Kriegshauser; William G Eversman; Rahmi Oklu
Journal:  Cardiovasc Diagn Ther       Date:  2017-12

Review 4.  Is there an optimal "door to cath time" in the treatment of acute pulmonary embolism with catheter-directed thrombolysis?

Authors:  Aranyak Rawal; Devarshi Ardeshna; Kirstin Hesterberg; Brandon Cave; Uzoma N Ibebuogu; Rami N Khouzam
Journal:  Ann Transl Med       Date:  2019-09

5.  Local Ultrasound-Facilitated Thrombolysis in High-Risk Pulmonary Embolism: First Dutch Experience.

Authors:  Maria A de Winter; Einar A Hart; Daniel A F van den Heuvel; Adriaan Moelker; Rutger J Lely; Karin A H Kaasjager; Pieter R Stella; Steven A J Chamuleau; Adriaan O Kraaijeveld; Mathilde Nijkeuter
Journal:  Cardiovasc Intervent Radiol       Date:  2019-03-12       Impact factor: 2.740

Review 6.  Ultrasound-Responsive Cavitation Nuclei for Therapy and Drug Delivery.

Authors:  Klazina Kooiman; Silke Roovers; Simone A G Langeveld; Robert T Kleven; Heleen Dewitte; Meaghan A O'Reilly; Jean-Michel Escoffre; Ayache Bouakaz; Martin D Verweij; Kullervo Hynynen; Ine Lentacker; Eleanor Stride; Christy K Holland
Journal:  Ultrasound Med Biol       Date:  2020-03-10       Impact factor: 2.998

7.  Catheter Directed Thrombolysis in the Treatment of Acute Pulmonary Embolism: Early Hemodynamic Recovery and Improvement in Prognosis.

Authors:  Qinglong Guan; Xiaofei Wang; Chenglong Liu; Yuan Gao; Haibo Chen; Gang Li
Journal:  Biomed Res Int       Date:  2022-03-24       Impact factor: 3.411

8.  EHA Guidelines on Management of Antithrombotic Treatments in Thrombocytopenic Patients With Cancer.

Authors:  Anna Falanga; Avi Leader; Chiara Ambaglio; Zsuzsa Bagoly; Giancarlo Castaman; Ismail Elalamy; Ramon Lecumberri; Alexander Niessner; Ingrid Pabinger; Sebastian Szmit; Alice Trinchero; Hugo Ten Cate; Bianca Rocca
Journal:  Hemasphere       Date:  2022-07-13

9.  Treatment of high- and intermediate-risk pulmonary embolism using the AngioJet percutaneous mechanical thrombectomy system in patients with contraindications for thrombolytic treatment - a pilot study.

Authors:  Paweł Latacz; Marian Simka; Pawel Brzegowy; Wojciech Serednicki; Ewa Konduracka; Wojciech Mrowiecki; Agnieszka Słowik; Bartłomiej Łasocha; Tomasz Mrowiecki; Tadeusz Popiela
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2018-05-16       Impact factor: 1.195

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.